3,0
15. Mai 2024
Aktueller Mitarbeiter, mehr als 1 Jahr
Cambridge, East of England, England
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Really smart people Great facilities Interesting science
Kontras
Has been described as a passive-aggressive organisation which is very true - hard to get things done People generally unhappy and disengaged, due to low pay, high workloads and little transparency from upper management Not the most innovative of Big pharma - content to fast follow and acquire late stage assets once validated rather than invest in their own original R&D Hard to get promoted and unclear what is required to progress